美法仑氟苯达唑联合地塞米松治疗复发难治多发性骨髓瘤的长期生存随访:II期O-12-M1研究
II期O-12-M1研究更新分析评估美法仑氟苯达唑联合地塞米松治疗既往≥2线(含硼替佐米和来那度胺)复发难治多发性骨髓瘤的长期生存。
要点
- 部分缓解及以上率为31%。
核心结论
- 美法仑氟苯达唑联合地塞米松在复发难治多发性骨髓瘤患者中产生持续长期临床获益。
研究设计与样本
- II期O-12-M1研究更新生存分析,纳入既往≥2线治疗(含硼替佐米和来那度胺)的复发难治多发性骨髓瘤患者。
主要发现
- 部分缓解及以上率为31%。
临床怎么用
- 对于既往多线治疗(含硼替佐米和来那度胺)的复发难治多发性骨髓瘤,可考虑美法仑氟苯达唑联合地塞米松。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.
引用
- Bringhen S, Voorhees PM, Plesner T, et al. Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. Br J Haematol. 2021. PMID: 33403663. doi:10.1111/bjh.17302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。